You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, Non-Hodgkin

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NHL, NHL, Relapsed, Adult Trial in United States (CLN-978)

Recruiting
  • NHL
  • NHL, Relapsed, Adult
  • Birmingham, Alabama
  • +4 more
May 31, 2023

Solid Tumor, Non-Hodgkin Lymphoma Trial in Guangzhou, Shanghai (ADG106)

Active, not recruiting
  • Solid Tumor
  • Non-Hodgkin Lymphoma
  • Guangzhou, Guangdong, China
  • +1 more
Oct 15, 2022

Aggressive Non-Hodgkin Lymphoma, CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma Trial in Rochester (Laboratory Biomarker

Suspended
  • Recurrent Aggressive Non-Hodgkin Lymphoma
  • +5 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 12, 2023

CB-Long-Term Safety Study (CB-LTSS)

Enrolling by invitation
  • Lymphoma, Non-Hodgkin
  • +7 more
  • Allogeneic CAR-T therapy
  • Irvine, California
  • +3 more
Nov 18, 2022

Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed Trial in United States (MT-601)

Recruiting
  • Non-Hodgkin Lymphoma, Adult
  • +3 more
  • Duarte, California
  • +3 more
Apr 4, 2023

Non-Hodgkin Lymphoma, Multiple Myeloma Trial in China (Maplirpacept)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Multiple Myeloma
  • Beijing, Beijing, China
  • +3 more
May 31, 2023

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • +4 more
  • Birmingham, United Kingdom
  • +5 more
Sep 18, 2023

Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker

Active, not recruiting
Has Results
  • Follicular Lymphoma
  • +2 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 6, 2022

Non-hodgkin Lymphoma,B Cell Trial (CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection)

Not yet recruiting
  • Non-hodgkin Lymphoma,B Cell
  • CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
  • (no location specified)
Feb 14, 2023

CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)

Recruiting
  • CD20-positive Non-Hodgkin Lymphoma
  • EX103 injection
  • Zhengzhou, Henan, China
  • +3 more
Aug 28, 2023

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma Trial in Isehara, Chuo-ku (tazemetostat)

Completed
Has Results
  • Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
  • Isehara, Kanagawa, Japan
  • +1 more
Apr 6, 2022

Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of

Active, not recruiting
  • Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
  • Copanlisib (BAY80-6946)
  • Multiple Locations, Taiwan
    Many Locations
Jan 31, 2023

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Beijing (JS203 for Injection)

Not yet recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • JS203 for Injection
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 11, 2022

Non-Hodgkin's Lymphoma Trial (MBS303)

Not yet recruiting
  • Non-Hodgkin's Lymphoma
  • (no location specified)
Apr 6, 2023

Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in United States (CB-010,

Recruiting
  • Lymphoma, Non-Hodgkin
  • +6 more
  • CB-010
  • +2 more
  • Scottsdale, Arizona
  • +7 more
Aug 19, 2022

B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (AS-1763)

Not yet recruiting
  • B-cell Malignancy
  • +7 more
  • (no location specified)
Oct 26, 2022

NonHodgkin's Lymphoma Refractory Trial in El Segundo (N803, CD19t-haNK suspension, Cyclophosphamide)

Not yet recruiting
  • NonHodgkin's Lymphoma Refractory
  • El Segundo, California
    CSSIFM
Nov 9, 2022

B-Cell Non-Hodgkin Lymphoma, Multiple Myeloma Trial in Duarte (Best Practice, Cognitive Intervention, Comprehensive Geriatric

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • Multiple Myeloma
  • Best Practice
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Sep 19, 2023

Recurrent Histiocytic and Dendritic Cell Tumor, Recurrent Non-Hodgkin Lymphoma, Refractory Histiocytic and Dendritic Cell Tumor

Recruiting
  • Recurrent Histiocytic and Dendritic Cell Neoplasm
  • +3 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Dec 5, 2022

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
Has Results
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 20, 2022

Non-hodgkin's Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Non-hodgkin's Lymphoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jan 12, 2023

Stem Cell Transplantation, MDS, Leukemia, Myeloid, Acute Trial in Miami (Mindfulness-based Music Therapy (MBMT), Mindfulness

Not yet recruiting
  • Stem Cell Transplantation
  • +4 more
  • Mindfulness-based Music Therapy (MBMT)
  • Mindfulness Meditation (MM)
  • Miami, Florida
    University of Miami
Aug 1, 2023

Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell Trial in New York (Pharmacokinetics)

Recruiting
  • Lymphoma
  • +4 more
  • Pharmacokinetics
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Sep 12, 2022

Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult Trial in Boston (Epcoritamab, Rituximab)

Not yet recruiting
  • Follicular Lymphoma
  • Low Grade Non-Hodgkin's Lymphoma, Adult
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Mar 13, 2023

Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in Changsha, Suzhou (U16)

Recruiting
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Changsha, Hunan, China
  • +1 more
Mar 13, 2023